Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 2/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561285 | 0.82 | PTGER1 (0.55) | PTGER1PDE4D | |
| SCHEMBL560583 | 0.82 | PTGER1 (0.71) | PTGER1 | |
| SCHEMBL561984 | 0.82 | PTGER1 (0.55) | PTGER1 | |
| SCHEMBL561382 | 0.82 | SMN1; SMN2 (0.47) | PTGER1ANO1S1PR4KCNMA1POLB | |
| SCHEMBL560895 | 0.79 | SCD (0.40) | PTGER1CACNA1GCACNA1HCACNA1INPY5R | |
| SCHEMBL561805 | 0.75 | PTGER1 (0.41) | PTGER1SCDSCD5 | |
| SCHEMBL560685 | 0.72 | PTGER1 (0.41) | PTGER1CNR1PDE4D | |
| SCHEMBL30771732 | 0.71 | P2RX1 (0.64) | KCNMA1 | |
| SCHEMBL18341307 | 0.71 | P2RX1 (0.64) | KCNMA1 | |
| SCHEMBL561292 | 0.71 | PTGER1 (0.40) | PTGER1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2010122088-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | RYR2, PAICS, CTRC | PTGER1 1951/4885ANO1 607/4885S1PR4 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.